X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
SIGA will drive international promotion activities for oral TPOXX, a novel small-molecule drug, approved by the FDA for the treatment of smallpox, while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SIGA Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2024
Details:
TPOXX (tecovirimat), also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Tecovirimat (also known as TPOXX®) prevents the virus from leaving infected cells, stopping its spread within the body for monkeypox based on promising results from initial studies in animals and evidence of safety in healthy human volunteers.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
The Company has also demonstrated the ability of NV-387 to encapsulate and improve the pharmacokinetics and pharmacodynamics of a very difficult drug, namely remdesivir, that is formulated in a cyclodextrin-based formulation at present (Veklury® Gilead).
Lead Product(s): Tecovirimat,NV-387
Therapeutic Area: Infections and Infectious Diseases Product Name: NV-387
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.
Lead Product(s): Vaccinia-based Cancer Therapy,Tecovirimat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: KaliVir Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 15, 2022
Details:
TPOXX (tecovirimat, ST-246®), a novel small-molecule drug, is an orthopoxvirus VP37 envelope wrapping protein inhibits the viral maturation of variola virus and other poxviruses by preventing the formation of a secondary viral envelope.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Patheon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Tecovirimat (TPOXX) was approved by the European Medicines Agency (EMA) in January 2022 with a broader label that covers the treatment of smallpox, monkeypox, cowpox, and complications from vaccination for smallpox.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Funding May 12, 2022
Details:
TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
TPOXX (tecovirimat) receive EMA approval for use in the EU as an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Meridian Medical Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
TPOXX®(Tecovirimat) orally administered IV formulation antiviral drug, is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein indicated for the treatment of human smallpox disease caused by variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
TPOXX® (tecovirimat) also known as ST-246® is an oral and IV formulation antiviral drug for the treatment of human smallpox disease Under the agreement, Oxford University will sponsor the protocol and study in CAR, and SIGA will provide up to 500 courses of TPOXX at no cost.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Oxford
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 29, 2021
Details:
Public Health Agency of Canada has contracted Meridian Medical Technologies for the purchase up to approximately $33 million of oral TPOXX® within five years. TPOXX® is an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Public Health Agency of Canada
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
Details:
Public Health Agency of Canada (PHAC) has issued an advanced contract award notice (ACAN), indicating that the PHAC intends to purchase up to 33,300 courses of oral TPOXX® (tecovirimat) within five years as specified in the ACAN.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Tpoxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Public Health Agency of Canada
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 08, 2020
Details:
SIGA has filed its application for oral tecovirimat seeking a broader label indication covering the treatment of smallpox, monkeypox, cowpox, and complications from Vaccinia infection. SIGA is targeting approval for the second half of 2021.
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: ST-246
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the deliveries of oral TPOXX® (tecovirimat) to the U.S. Department of Health and Human Services (HHS).
Lead Product(s): Tecovirimat
Therapeutic Area: Immunology Product Name: Tpoxx
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $414.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 25, 2020
Details:
Funding will support work necessary to gain a potential label expansion from the U.S. FDA for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox.
Lead Product(s): Tecovirimat
Therapeutic Area: Immunology Product Name: Tpoxx
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: JPEO-CBRND
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 15, 2020
Details:
Funding is directed towards procurement of oral TPOXX for the treatment of smallpox (tecovirimat).
Lead Product(s): Tecovirimat
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $101.3 million Upfront Cash: Undisclosed
Deal Type: Funding April 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
